Eaton Vance Management Viking Therapeutics, Inc. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
Shares
3 transactions
Others Institutions Holding VKTX
# of Institutions
480Shares Held
66.2MCall Options Held
6.24MPut Options Held
3.01M-
Vanguard Group Inc Valley Forge, PA10.1MShares$691 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$413 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$351 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$145 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$127 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.25B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...